AstraZeneca completes USD 2 billion equity investment in Summit Therapeutics

Bitget2026/10/05 11:01

AstraZeneca closed a USD 2 billion strategic equity investment in Summit Therapeutics to support development of PD-1/VEGF bispecific antibody ivonescimab. AstraZeneca bought about 108,955 shares of preferred stock, convertible into common stock at a 1:1,000 ratio. Implied common stock price was USD 18.36 per share, a premium to the closing price when the deal was announced. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610050700BIZWIRE_USPR_____20261005_BW990054) on October 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

A List of the 15 Altcoins Most Searched for in Recent Hours Has Been Published

BitcoinSistemi•2026/10/11 12:24

Michael Saylor releases bitcoin Tracker information again, possibly hinting at increasing BTC holdings

BlockBeats•2026/10/11 12:13

Crypto Pundit Says If You Are Holding XLM, Read This

TimesTabloid•2026/10/11 12:00

International gold prices are approaching the $4,200 mark, and Wall Street is bullish on next week's market.

新浪财经•2026/10/11 11:05